Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc. (INO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ino · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Inovio Pharmaceuticals, Inc. (INO) measures how much investors pay for each dollar of the company's trailing earnings. INO's current PE ratio of N/A is calculated by dividing its stock price of $1.09 by its TTM earnings per share of -$0.12.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Inovio Pharmaceuticals, Inc.You INO | $58M | N/A | — | -$0.12 |
 Acumen Pharmaceuticals, Inc. ABOS | $131M | N/A | — | -$2.00 |
 Actuate Therapeutics Inc ACTU | $44M | N/A | — | -$1.06 |
 Agenus Inc. AGEN | $131M | 811.87x | — | $0.00 |
 Alector, Inc. ALEC | $182M | N/A | — | -$1.39 |
 Fate Therapeutics, Inc. FATE | $223M | N/A | — | -$1.15 |
 Opus Genetics, Inc. IRD | $328M | N/A | — | -$0.08 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.18 | — | |
2024-12-31 FY2024 | — | $-3.95 | — | |
2023-12-31 FY2023 | — | $-6.09 | — | |
2022-12-31 FY2022 | — | $-14.07 | — | |
2021-12-31 FY2021 | — | $-1.41 | — | |
2020-12-31 FY2020 | — | $-1.01 | — | |
2019-12-31 FY2019 | — | $-0.96 | — | |
2018-12-31 FY2018 | — | $-1.05 | — | |
2017-12-31 FY2017 | — | $-1.08 | — | |
2016-12-31 FY2016 | — | $-1.01 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Inovio Pharmaceuticals, Inc. (INO) measures how much investors pay for each dollar of the company's trailing earnings. INO's current PE ratio of N/A is calculated by dividing its stock price of $1.09 by its TTM earnings per share of -$0.12.
Frequently asked questions
INO pe ratio · 6 questionsINO's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.09 and TTM EPS of -$0.12. Data sourced from Financial Modeling Prep via INO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Inovio Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09